Spiriva Observational Study Measuring Saint George's Respiratory Questionnaire (SGRQ) in Routine Medical Practice in Central & Eastern European Region
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2009-11-01
- Last Posted Date
- 2014-04-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 4852
- Registration Number
- NCT01006135
- Locations
- 🇵🇱
Boehringer Ingelheim Investigational Site 229, Nowy Sacz, Poland
🇵🇱Boehringer Ingelheim Investigational Site 234, Olawa, Poland
🇵🇱Boehringer Ingelheim Investigational Site 238, Olesnica, Poland
A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]
- First Posted Date
- 2009-10-29
- Last Posted Date
- 2013-12-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 43
- Registration Number
- NCT01003899
- Locations
- 🇰🇷
1200.72.8201 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of
🇰🇷1200.72.8203 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of
🇰🇷1200.72.8202 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of
Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
- First Posted Date
- 2009-10-29
- Last Posted Date
- 2017-10-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 125
- Registration Number
- NCT01004003
- Locations
- 🇫🇷
1199.37.33002 Boehringer Ingelheim Investigational Site, Paris, France
🇩🇪1199.37.49003 Boehringer Ingelheim Investigational Site, München, Germany
🇵🇱1199.37.48003 Boehringer Ingelheim Investigational Site, Warsaw, Poland
Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.
- First Posted Date
- 2009-10-20
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 70
- Registration Number
- NCT00998296
- Locations
- 🇫🇷
1239.14.3301A Boehringer Ingelheim Investigational Site, Villejuif Cedex, France
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 278
- Registration Number
- NCT00996658
- Locations
- 🇵🇭
1218.61.63004 Boehringer Ingelheim Investigational Site, Cebu City, Philippines
🇵🇭1218.61.63002 Boehringer Ingelheim Investigational Site, Davao City, Philippines
🇺🇸1218.61.01042 Boehringer Ingelheim Investigational Site, Paramount, California, United States
Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2009-10-12
- Last Posted Date
- 2015-10-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 44
- Registration Number
- NCT00993499
- Locations
- 🇪🇸
1200.70.34002 Boehringer Ingelheim Investigational Site, Zaragoza, Spain
🇪🇸1200.70.34009 Boehringer Ingelheim Investigational Site, Barcelona, Spain
🇪🇸1200.70.34006 Boehringer Ingelheim Investigational Site, Girona, Spain
A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients
- First Posted Date
- 2009-10-01
- Last Posted Date
- 2016-03-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 134
- Registration Number
- NCT00987935
- Locations
- 🇨🇳
1199.39.88604 Boehringer Ingelheim Investigational Site, Taoyuan County, Taiwan
🇨🇳1199.39.88606 Boehringer Ingelheim Investigational Site, Changhua, Taiwan
🇨🇳1199.39.88603 Boehringer Ingelheim Investigational Site, Taipei, Taiwan
Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2009-09-25
- Last Posted Date
- 2015-09-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 160
- Registration Number
- NCT00984620
- Locations
- 🇺🇸
1220.40.006 Boehringer Ingelheim Investigational Site, Germantown, Tennessee, United States
🇦🇹1220.40.4301 Boehringer Ingelheim Investigational Site, Wien, Austria
🇺🇸1220.40.003 Boehringer Ingelheim Investigational Site, Nashville, Tennessee, United States
An Observational Cohort Study to Evaluate the Safety and Efficacy of Micardis Tablets Taken Once Daily at 40 mg/Day and 80 mg/Day in Hypertensive Patients Under Real Life Conditions in Usual Clinical Practice
- Conditions
- Hypertension
- First Posted Date
- 2009-09-23
- Last Posted Date
- 2014-04-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 987
- Registration Number
- NCT00982735
BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: BIBF 1120 M + PemetrexedDrug: BIBF 1120 RD + PemetrexedDrug: BIBF 1120 Placebo + PemetrexedDrug: BIBF 1120 H + PemetrexedDrug: BIBF 1120 L + Pemetrexed
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 19
- Registration Number
- NCT00979576
- Locations
- 🇯🇵
1199.28.003 Boehringer Ingelheim Investigational Site, Chiba,Kashiwa, Japan
🇯🇵1199.28.002 Boehringer Ingelheim Investigational Site, Miyakojima-ku, Osaka, Japan
🇯🇵1199.28.001 Boehringer Ingelheim Investigational Site, Osaka-Sayama, Osaka, Japan